![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1629904
¼¼°èÀÇ ÀÇ·á¿ë ÀÓÇöõÆ® ½ÃÀå(2025-2033³â)Global Medical Implants Market - 2025-2033 |
¼¼°è ÀÇ·á¿ë ÀÓÇöõÆ® ½ÃÀåÀº 2024³â¿¡ 1,175¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. 2033³â¿¡´Â 2,249¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2025-2033³â°£ 7.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
ÀÇ·á¿ë ÀÓÇöõÆ®´Â ¼ö¼úÀû ¶Ç´Â ºñ¼ö¼úÀûÀ¸·Î ü³» ¶Ç´Â üǥ¸é¿¡ »ðÀÔµÇ¾î »ýü ±¸Á¶¸¦ ´ëü, ÁöÁö, °È, ±â´É ȸº¹ ¹× ½É¹ÌÀû °³¼±À» À§ÇØ »ç¿ëµÇ´Â ÀåÄ¡ÀÔ´Ï´Ù. ÀÓÇöõÆ®´Â º´Àû »óÅÂ¿Í ¿øÇÏ´Â °á°ú¿¡ µû¶ó ¿µ±¸ÀûÀ̰ųª Á¦°ÅÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. ÀÓÇöõÆ®´Â ÀϹÝÀûÀ¸·Î Á¤Çü¿Ü°ú, ½ÉÀåÇÐ, ½Å°æÇÐ, Ä¡°ú, ¹Ì¿ë¿Ü°ú µî ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼ »ç¿ëµË´Ï´Ù. ÀÇ·á¿ë ÀÓÇöõÆ®ÀÇ °³¹ß ¹× »ç¿ëÀº ¾ÈÀü¼º, ±â´É¼º ¹× ȯÀÚ º¹Áö¸¦ º¸ÀåÇϱâ À§ÇØ Àç·á °úÇÐ, »ý¹° ÀÇÇÐ °øÇÐ ¹× ¿Ü°ú ¼ö¼ú ½Ç½ÀÀ» Æ÷ÇÔÇÑ ´ÙÇÐÁ¦Àû Àü¹® Áö½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù.
ÀÇ·á¿ë ÀÓÇöõÆ®ÀÇ ¼¼°è ¼ö¿ä´Â ÀÇ·á±â¼úÀÇ ¹ßÀü°ú ¸¸¼ºÁúȯ Áõ°¡¿¡ ÈûÀÔ¾î ºü¸£°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ÀÇ»çÇùȸ¿¡ µû¸£¸é ¹Ì±¹ÀÎ 10¸í Áß 1¸í(¾à 10%)Àº ÀÏ»ý µ¿¾È ¾îµò°¡¿¡ ÀÇ·á±â±â¸¦ À̽ÄÇÏ°Ô µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â °í·É Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ ¹× °üÀý¿° µîÀÇ Áúº´ À¯Çà, »ýüÀç·á ¹× Àúħ½À ¼ö¼ú ±â¼úÀÇ ¹ßÀü µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.
¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ
ÀÇ·á¿ë ÀÓÇöõÆ®ÀÇ ±â¼ú ¹ßÀüÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
ÀÇ·á¿ë ÀÓÇöõÆ®ÀÇ ±â¼ú ¹ßÀüÀº ÀÇ·á¿ë ÀÓÇöõÆ® ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÏ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ýü ÀûÇÕ¼º, °µµ ¹× ³»±¸¼ºÀ¸·Î ÀÎÇØ »ýü °íºÐÀÚ ¹× »ýºÐÇؼº ÀÓÇöõÆ®¿Í °°Àº »ýü Àç·á°¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓÇöõÆ®´Â ¸é¿ª ¹ÝÀÀÀÇ À§ÇèÀ» ÁÙÀÌ°í ȯÀÚÀÇ ÀÓÇöõÆ® ¼ö¿ë¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.
¿¹¸¦ µé¾î, 2024³â 8¿ù, ½ºÆ®¶óÀÌÄ¿´Â Àεµ¿¡¼ ¼¼°è ÃÖÃÊÀÇ »ýºÐÇؼº °ßºÀÇÏ Ç³¼± ÀÓÇöõÆ® 'InSpace'¸¦ Ãâ½ÃÇØ ¾î±ú °üÀý ±â´É Àå¾ÖÀÇ °¡Àå ÈçÇÑ ¿øÀÎ Áß ÇϳªÀÎ °Å´ë ȸÀü±Ù°³ ÆÄ¿(MIRCT)À» °üÀý°æÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. InSpace dz¼± ÀÓÇöõÆ®´Â ºÀÇÕÀ̳ª °íÁ¤ ÀåÄ¡ ¾øÀÌ °ßºÀÇÏ °ø°£À» º¹¿øÇϵµ·Ï ¼³°èµÇ¾î ¾î±úÀÇ ¿òÁ÷ÀÓ°ú ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ¸·Î ÀÔÁõµÈ InSpace dz¼± ÀÓÇöõÆ®´Â ¿Ü°ú Àǻ翡°Ô ¾î±ú °üÀý Ä¡·áÀÇ »õ·Î¿î ¼±ÅÃÁö¸¦ Á¦°øÇÏ°í ȯÀÚÀÇ ¿ä±¸¿¡ ºÎÀÀÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.
3D ÇÁ¸°ÆÃÀº ȯÀÚ °íÀ¯ÀÇ ÇغÎÇÐÀû ÇÊ¿ä¿¡ µû¶ó ¸ÂÃãÇüÀ¸·Î Á¦ÀÛÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ÀÓÇöõÆ® Á¦Á¶¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ ±â¼úÀº ´õ ÀûÇÕÇÏ°í, ´õ È¿°úÀûÀ̸ç, Á¤¹ÐÇÏ°í º¹ÀâÇÑ ¸ÂÃãÇü ÀÓÇöõÆ®¸¦ Á¦ÀÛÇÏ¿© ¼ö¼ú °á°ú¸¦ °³¼±Çϸç, 3D ÇÁ¸°Æà ÀÓÇöõÆ® ½ÃÀåÀº ºñ¿ë È¿À²ÀûÀÌ°í ªÀº ¸®µå ŸÀÓÀ¸·Î ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» »ý»êÇÒ ¼ö Àֱ⠶§¹®¿¡ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2024³â 4¿ù 3D Systems´Â 3D ÇÁ¸°ÆÃµÈ È¯ÀÚ Àü¿ë µÎ°³°ñ ÀÓÇöõÆ® ¼Ö·ç¼ÇÀÎ VSP PEEK Cranial ImplantÀÇ ½ÄÇ°ÀǾ౹(FDA) 510(k) ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¼¼ºÐÈ ¹× 3D ¸ðµ¨¸µ ¼ÒÇÁÆ®¿þ¾î, 3D Systems EXT 220 MED 3D ÇÁ¸°ÅÍ, Evonik VESTAKEEP i4 3DF PEEK(Polyetheretherketone) ¹× »çÀü Á¤ÀÇµÈ Á¦Á¶ °øÁ¤À¸·Î ±¸¼ºµÈ ¿Ïº®ÇÑ FDA ½ÂÀÎ ¿öÅ©Ç÷ο츦 Æ÷ÇÔÇÕ´Ï´Ù. Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ºÎ°¡ÀûÀÎ Á¦Á¶ ¼Ö·ç¼ÇÀ» È°¿ëÇÔÀ¸·Î½á ±âÁ¸ ±â°è °¡°øÀ¸·Î Á¦Á¶µÈ À¯»çÇÑ ÀÓÇöõÆ®º¸´Ù ÃÖ´ë 85% ÀûÀº Àç·á·Î ȯÀÚº° µÎ°³°ñ ÀÓÇöõÆ®¸¦ Á¦Á¶ÇÒ ¼ö ÀÖ¾î, ÀÓÇöõÆ®¿ë PEEK¿Í °°Àº °í°¡ÀÇ ¿øÀÚÀç ºñ¿ëÀ» Å©°Ô Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.
°í°¡ÀÇ ÀÓÇöõÆ® ºñ¿ë
°í°¡ÀÇ ÀÇ·á¿ë ÀÓÇöõÆ® ºñ¿ëÀº ƯÈ÷ Àú¼Òµæ Áö¿ª°ú °æÁ¦ÀûÀ¸·Î Ãë¾àÇÑ È¯ÀÚµéÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ¿© ½ÃÀå ¼ºÀåÀ» Å©°Ô ÀúÇØÇÏ°í ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú¿ë Àΰø°üÀý°ú °°Àº °í±Þ ÀÓÇöõÆ®¿¡´Â ƼŸ´½ ÇÕ±ÝÀ̳ª ¼¼¶ó¹Í°ú °°Àº °í°¡ÀÇ Àç·á°¡ »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹¾Æ Á¦Á¶ ¹× ±¸¸Å ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. ÀÌ·Î ÀÎÇØ ÀÓÇöõÆ®ÀÇ Ãʱ⠰¡°ÝÀÌ ³ô¾ÆÁ® ¸¹Àº ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡¼ °¨´çÇÒ ¼ö ¾ø´Â ¼öÁرîÁö ¿Ã¶ó°©´Ï´Ù.
¿¹¸¦ µé¾î, Journal of Orthopaedic BusinessÁö¿¡ µû¸£¸é, Ç¥ÁØ ½½°üÀý ÀÓÇöõÆ®ÀÇ Æò±Õ ºñ¿ëÀº 5,336´Þ·¯+-1,671´Þ·¯À̸ç, 1Â÷ Àΰø½½°üÀý Àüġȯ¼ú(TKA)ÀÇ Æò±Õ ÃÑ ºñ¿ëÀº 23,907´Þ·¯+-9,514´Þ·¯·Î ³ªÅ¸³µ½À´Ï´Ù. Ç¥ÁØ Àΰø½½°üÀý ºñ¿ëÀº 1Â÷ Àΰø½½°üÀý Àüġȯ¼ú ÃÑ ºñ¿ëÀÇ 22.3%¸¦ Â÷ÁöÇÕ´Ï´Ù.
°í°¡ÀÇ ÀÓÇöõÆ® ºñ¿ëÀ¸·Î ÀÎÇØ ÀÇ·á ½Ã½ºÅÛ¿¡ °æÁ¦Àû ºÎ´ãÀÌ °¡Áߵǰí ÀÖ½À´Ï´Ù. ¹Ì±¹°ú °°Àº ±¹°¡¿¡¼´Â ÀÇ·áºñ ÁöÃâÀÇ »ó´ç ºÎºÐÀÌ ÀÓÇöõÆ®¸¦ Æ÷ÇÔÇÑ °íºñ¿ë ½Ã¼ú¿¡ ÁýÁߵǾî ÀÖ½À´Ï´Ù. À̴ ȯÀÚÀÇ º¸Çè·á¿Í º»ÀÎ ºÎ´ã±ÝÀÌ ³ô¾ÆÁ® Àüü ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, Ä¡°ú¿ë ÀÓÇöõÆ®´Â Ä¡¾Æ 1°³´ç 3000-7000´Þ·¯ÀÇ ºñ¿ëÀÌ µì´Ï´Ù. ÀÌ °¡°Ý¿¡´Â ÀÓÇöõÆ® º»Ã¼(¿Ü°úÀû ¼ö¼ú·Î ÅλÀ¿¡ À̽ÄÇϴ ƼŸ´½ ±âµÕÀÎ ÀÓÇöõÆ® º»Ã¼, ¾î¹öÆ®¸ÕÆ®, Å©¶ó¿îÀÌ Æ÷ÇԵ˴ϴÙ. Å©¶ó¿îÀº º¸Åë Æ÷¼¼¸°À̳ª Áö¸£ÄڴϾƷΠ¸¸µé¾îÁ® ÀÚ¿¬ Ä¡¾ÆÀÇ ¸ð¾ç°ú ±â´ÉÀ» ¸ð¹æÇÕ´Ï´Ù.
The global medical implants market reached US$ 117.5 billion in 2024 and is expected to reach US$ 224.9 billion by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.
A medical implant is a device that is surgically or non-surgically placed inside or on the surface of the body to replace, support, or enhance a biological structure, restore function, or improve aesthetics. Implants are designed to either be permanent or removable, depending on the medical condition or the desired outcome. They are typically used in various medical fields, including orthopedics, cardiology, neurology, dentistry, and cosmetic surgery. Medical implant development and utilization involve interdisciplinary expertise in materials science, biomedical engineering, and surgical practices to ensure safety, functionality, and patient well-being.
The global demand for medical implants is growing rapidly, driven by advancements in medical technology and the rising prevalence of chronic diseases. For instance, according to the American Medical Association, one in 10 Americans (about 10% of Americans) will have a medical device implanted into their bodies at some point in their lifetimes. Key factors driving this demand include the increasing geriatric population, the prevalence of conditions like cardiovascular diseases and arthritis, and advancements in biomaterials and minimally invasive surgical techniques.
Market Dynamics: Drivers & Restraints
Rising technological advancements in medical implants
The rising technological advancements in medical implants are significantly driving the growth of the medical implants market and are expected to drive the market over the forecast period. Biomaterials such as biopolymers and biodegradable implants are being increasingly used due to their biocompatibility, strength and durability. These implants reduce the risk of immune responses and improve patient acceptance of implants.
For instance, in August 2024, Stryker launched a first-of-its-kind biodegradable subacromial balloon implant, InSpace, the first balloon implant for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs), in India. MIRCTs are one of the most common causes of shoulder dysfunction. InSpace provides a new option for surgeons in their shoulder continuum of care that allows them to better meet the needs of their patients. The InSpace balloon implant is designed to restore the subacromial space without requiring sutures or fixation devices and has been demonstrated to improve shoulder motion and function.
3D printing has revolutionized the production of implants by allowing customization based on patient-specific anatomical needs. This technology improves surgical outcomes by creating precise, complex and tailored implants that fit better and are more effective. The market for 3D-printed implants is expected to grow due to its ability to produce cost-effective, customizable solutions with shorter lead times.
For instance, in April 2024, 3D Systems announced the Food and Drug Administration (FDA) 510(k) clearance for its 3D-printed, patient-specific cranial implant solution, VSP PEEK Cranial Implant. VSP PEEK Cranial Implant includes a complete FDA-cleared workflow comprising segmentation and 3D modeling software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP i4 3DF PEEK (polyetheretherketone), and a pre-defined production process. By utilizing additive manufacturing solutions, this technology can produce patient-specific cranial implants with up to 85% less material than similar implants produced by traditional machining, which can lead to significant cost savings for an expensive raw material like implantable PEEK.
The high cost of the implants
The high cost of medical implants significantly hampers the growth of the market by limiting access, especially in low-income regions and among economically disadvantaged patients. High-end implants, such as orthopedic joint replacements, often use expensive materials like titanium alloys and ceramics, which are costly to manufacture and purchase. This increases the initial price of the implant, making it unaffordable for many patients and healthcare systems.
For instance, according to the Journal of Orthopaedic Business, the mean cost of the standard knee implant was $5,336 +- $1,671 and the mean total cost of primary total knee arthroplasty (TKA) was $23,907 +- $9,514. The cost of the standard knee implant contributes to 22.3% of the total cost of a primary total knee arthroplasty.
The high cost of implants creates an economic burden on healthcare systems. In countries like the U.S., a significant portion of healthcare spending is directed toward high-cost procedures involving implants. This can lead to higher insurance premiums and out-of-pocket expenses for patients, affecting overall market growth.
For instance, dental implants cost between $3000 and $7000 for one tooth. This price includes the implant itself, which is the titanium post that's surgically placed into the jawbone, as well as the abutment and the crown. The crown, usually made of porcelain or zirconia, mimics the natural tooth's look and function.
The global medical implants market is segmented based on product type, material, application, end-user and region.
The orthopedic implants segment is expected to dominate the medical implants market share
The global aging population is a significant driver for orthopedic implants. As the population ages, there is a rise in conditions like arthritis, osteoporosis, and fractures due to falls, leading to higher demand for implants such as joint replacements and spinal devices. For instance, according to the Bone and Joint Burden Organization, roughly one in four (24.5%) musculoskeletal diseases occurs in persons aged 65 years and older. Almost 40% of musculoskeletal diseases occur among persons aged 45 to 64 years, increasing demand for orthopedic implants.
Advances in orthopedic implants have enabled the production of customized implants that are more precise and better suited to individual patient anatomies. This has improved outcomes and reduced recovery times for procedures such as hip and knee replacements. For instance, in April 2024, Onkos Surgical cleared that the U.S. Food & Drug Administration (FDA) granted a De Novo approval for its novel antibacterial-coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
Major players in the orthopedic implants market, such as Johnson & Johnson, Stryker and Zimmer Biomet, are driving growth through continuous innovation and acquisition of smaller companies with advanced technologies. Their extensive product portfolios covering joint replacement systems, spine implants, and trauma devices are pivotal in maintaining dominance in the market.
For instance, in December 2024, Zimmer Biomet Holdings, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona SoluTion Porous Plasma Spray (PPS) Femur, a total knee implant component offering an alternative for patients with sensitivities to bone cement and/or metal. The Persona SoluTion PPS Femur features a porous coating for cementless fixation and leverages a proprietary surface treatment designed to enhance wear performance.
North America is expected to hold a significant position in the medical implants market share
North America, particularly the United States, boasts a highly developed healthcare system with access to advanced medical technologies and skilled healthcare providers. The presence of well-equipped hospitals and specialized treatment centers facilitates the adoption of new medical implants. For instance, according to the American Academy of Implant Dentistry, in the US, over a million are treated with dental implants each year (corresponding to 2.5 million implants).
North America is a hub for medical research and innovation. The collaboration between academic institutions, healthcare providers, and industry leaders accelerates the development of advanced medical implants. Companies like Medtronic, Johnson & Johnson, Boston Scientific and other emerging players are headquartered in the United States, where they conduct extensive R&D to develop cutting-edge medical devices. This environment supports the launch of new products and technologies, thereby maintaining North America's market dominance.
For instance, in December 2024, Mentor Worldwide LLC, part of Johnson & Johnson MedTech, announced the U.S. Food and Drug Administration (FDA) approved MENTOR MemoryGel Enhance Breast Implants for primary and revision reconstruction breast surgery in post-mastectomy women. This first-of-its-kind silicone gel-filled implant line features an expanded range of base widths, projections and volumes in an entirely new range of sizes extending from 930 cc to 1445 cc, the largest on the market. Mentor plans to commercially launch MemoryGel Enhance Breast Implants in the U.S. beginning in mid-2025.
Additionally, in October 2024, X-Bolt Orthopedics, an emerging innovator of orthopedic trauma devices, announced the successful completion of the first U.S. implant using its Pro-X1 Trochanteric Nailing System in Florida. This milestone marks the official commercial launch of the company's flagship product and signifies a major step forward in applying X-Bolt's technology for hip fracture treatment across the U.S.
Asia-Pacific is growing at the fastest pace in the medical implants market
The adoption of advanced technologies such as 3D printing, minimally invasive surgical techniques, and smart implants is growing in the APAC region. These technologies allow for customized implants, better surgical outcomes and quicker recovery times, which are especially attractive in densely populated regions with a high demand for cost-effective treatments.
For instance, in August 2024, Stryker, a global leader in medical technologies, launched InSpace, the first balloon implant for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs), in India. MIRCTs are one of the most common causes of shoulder dysfunction. InSpace provides a new option for surgeons in their shoulder continuum of care that allows them to better meet the needs of their patients.
Additionally, in September 2024, GC Aesthetics, a leading medical technology company committed to advancing women's health through innovative aesthetic and reconstructive breast solutions, launched the YOUTHLY brand in China, featuring its latest breast implant innovations: PERLE, Luna XT, and the latest version of The Round Collection, 100% filled.
The presence of global medical device manufacturers and increasing foreign direct investment in the healthcare sector are crucial factors. Companies like Zimmer Biomet (ZimVie), Medtronic, Johnson & Johnson, and Boston Scientific are expanding their footprint in APAC, either through local manufacturing facilities or distribution partnerships. These investments are boosting product availability and enabling quicker adoption of new medical technologies.
For instance, in February 2024, ZimVie Inc., a global life sciences leader in the dental and spine markets, launched TSX Implant in Japan. As ZimVie's largest dental implant market in APAC and the fifth largest market globally, Japan is of great strategic importance to ZimVie. The launch of TSX in Japan allows the company to compete head-to-head with premium market leaders in the dental implant space.
The major global players in the medical implants market include Stryker Corporation, Dentsply Sirona, ZimVie Inc., Johnson & Johnson, Zimmer Biomet Holdings, Inc., Smith+Nephew, Boston Scientific Corporation, Meril Life Sciences Pvt. Ltd., Cochlear Ltd., Wright Medical Group N.V. and among others.
The global medical implants market report delivers a detailed analysis with 70 key tables, more than 72 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE